Resultados: 4

    Clinical practice guideline on treating influenza in adult patients with Chinese patent medicines

    Pharmacol. res; 160 (), 2020
    Influenza is a major public health problem worldwide. Mutations and resistance development make the use of antiviral therapy challenging. Chinese patent medicines are often used to treat influenza in China and well tolerable. However, the misuse of Chinese patent medicines is common. We therefore aimed t...

    Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology

    Different therapies are currently used, considered, or proposed for the treatment of COVID-19; for many of those therapies, no appropriate assessment of effectiveness and safety was performed. This document aims to provide scientifically available evidence-based information in a transparent interpretatio...

    WHO Guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses: part II review of evidence

    This revised guidance is published in two parts. Part II documents the procedures followed in developing this guidance, together with a review of evidence and other new information on the pharmacological agents considered....

    WHO Guidelines for pharmacological management of pandemic Influenza A(H1N1) 2009 and other influenza viruses: part I recommendations

    The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection, as well their use for chemoprophylaxis. This guidance updates and replaces the recommendations published in A...